Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo. Gramatica A, Schwarzer R, Brantley W, Varco-Merth B, et al. J Virol 2021 Feb 3. pii: JVI.02393-20. doi: 10.1128/JVI.02393.

Read + Share

Amedeo Smart

Independent Medical Education

Gramatica A, Schwarzer R, Brantley W, Varco-Merth B, et al. Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo. J Virol 2021 Feb 3. pii: JVI.02393-20. doi: 10.1128/JVI.02393.
PMID: 33536176